TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET 41
1.4 CURRENCY AND PRICING 43
1.5 LIMITATIONS 43
1.6 MARKETS COVERED 43
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET: GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 DBMR MARKET POSITION GRID 54
2.7 DBMR VENDOR SHARE ANALYSIS 55
2.8 MULTIVARIATE MODELING 56
2.9 PRODUCTS LIFELINE CURVE 56
2.10 SECONDARY SOURCES 57
2.11 ASSUMPTIONS 57
3 MARKET OVERVIEW 58
3.1 DRIVERS 60
3.1.1 INVESTMENT IN R&D ACTIVITIES BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 60
3.1.2 RISING NUMBER OF DISEASES 61
3.1.3 GROWING GOVERNMENT INITIATIVES 63
3.2 RESTRAINTS 64
3.2.1 HIGH COST OF INSTRUMENTS 64
3.2.2 STRINGENT GOVERNMENT REGULATIONS 64
3.3 OPPORTUNITIES 65
3.3.1 AVAILIBILITY OF NUMBER OF TECHNIQUES FOR DETECTION OF MYCOPLASMA 65
3.3.2 STRATEGIC INITIATIVES BY VARIOUS COMPANIES 65
3.4 CHALLENGES 66
3.4.1 LACK OF SKILLED PROFESSIONALS 66
3.4.2 CHALLENEGES IN THE DIAGNOSIS OF MYCOPLASMA INFECTION 66
4 EXECUTIVE SUMMARY 67
5 PREMIUM INSIGHTS 70
6 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY PRODUCTS 72
6.1 OVERVIEW 73
6.2 KITS & REAGENTS 74
6.3 INSTRUMENTS 75
6.4 SERVICES 76
7 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY TECHNIQUES 77
7.1 OVERVIEW 78
7.2 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 79
7.3 POLYMERASE CHAIN REACTION 79
7.4 ELISA 80
7.5 DNA STAINING/INDIRECT ASSAY 81
7.6 ENZYMATIC METHODS 81
7.7 OTHERS 82
8 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY DISEASE AREA 83
8.1 OVERVIEW 84
8.2 RESPIRATORY 85
8.2.1 BY CAUSATIVE AGENT 85
8.2.1.1 MYCOPLASMA PNEUMONIAE 85
8.2.1.2 MYCOPLASMA HOMINIS 86
8.2.1.3 UREAPLASMA UREALYTICUM 86
8.2.1.4 MYCOPLASMA GENITALIUM 86
8.2.1.5 OTHERS 86
8.2.2 BY TECHNIQUE 86
8.2.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 86
8.2.2.2 POLYMERASE CHAIN REACTION 86
8.2.2.3 ELISA 86
8.2.2.4 DNA STAINING/INDIRECT ASSAY 87
8.2.2.5 ENZYMATIC METHODS 87
8.2.2.6 OTHERS 87
8.3 UROGENITAL 87
8.3.1 BY CAUSATIVE AGENT 88
8.3.1.1 MYCOPLASMA HOMINIS 88
8.3.1.2 UREAPLASMA UREALYTICUM 88
8.3.1.3 MYCOPLASMA GENITALIUM 88
8.3.1.4 MYCOPLASMA PNEUMONIAE 88
8.3.1.5 OTHERS 88
8.3.2 BY TECHNIQUE 89
8.3.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 89
8.3.2.2 POLYMERASE CHAIN REACTION 89
8.3.2.3 ELISA 89
8.3.2.4 DNA STAINING/INDIRECT ASSAY 89
8.3.2.5 ENZYMATIC METHODS 89
8.3.2.6 OTHERS 89
8.4 GASTROINTESTINAL 90
8.4.1 BY CAUSATIVE AGENT 90
8.4.1.1 MYCOPLASMA PNEUMONIAE 91
8.4.1.2 MYCOPLASMA HOMINIS 91
8.4.1.3 UREAPLASMA UREALYTICUM 91
8.4.1.4 MYCOPLASMA GENITALIUM 91
8.4.1.5 OTHERS 91
8.4.2 BY TECHNIQUE 91
8.4.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 91
8.4.2.2 POLYMERASE CHAIN REACTION 91
8.4.2.3 ELISA 92
8.4.2.4 DNA STAINING/INDIRECT ASSAY 92
8.4.2.5 ENZYMATIC METHODS 92
8.4.2.6 OTHERS 92
8.5 CARDIOVASCULAR 92
8.5.1 BY CAUSATIVE AGENT 93
8.5.1.1 MYCOPLASMA PNEUMONIAE 93
8.5.1.2 MYCOPLASMA HOMINIS 93
8.5.1.3 UREAPLASMA UREALYTICUM 93
8.5.1.4 MYCOPLASMA GENITALIUM 93
8.5.1.5 OTHERS 93
8.5.2 BY TECHNIQUE 94
8.5.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 94
8.5.2.2 POLYMERASE CHAIN REACTION 94
8.5.2.3 ELISA 94
8.5.2.4 DNA STAINING/INDIRECT ASSAY 94
8.5.2.5 ENZYMATIC METHODS 94
8.5.2.6 OTHERS 94
8.6 MUSCULOSKELETAL 95
8.6.1 BY CAUSATIVE AGENT 95
8.6.1.1 MYCOPLASMA PNEUMONIAE 96
8.6.1.2 MYCOPLASMA HOMINIS 96
8.6.1.3 UREAPLASMA UREALYTICUM 96
8.6.1.4 MYCOPLASMA GENITALIUM 96
8.6.1.5 OTHERS 96
8.6.2 BY TECHNIQUE 96
8.6.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 96
8.6.2.2 POLYMERASE CHAIN REACTION 96
8.6.2.3 ELISA 97
8.6.2.4 DNA STAINING/INDIRECT ASSAY 97
8.6.2.5 ENZYMATIC METHODS 97
8.6.2.6 OTHERS 97
8.7 OTHERS 97
8.7.1 BY CAUSATIVE AGENT 98
8.7.1.1 MYCOPLASMA PNEUMONIAE 98
8.7.1.2 MYCOPLASMA HOMINIS 98
8.7.1.3 UREAPLASMA UREALYTICUM 98
8.7.1.4 MYCOPLASMA GENITALIUM 98
8.7.1.5 OTHERS 98
8.7.2 BY TECHNIQUE 99
8.7.2.1 MICROBIAL CULTURE TECHNIQUES/DIRECT ASSAY 99
8.7.2.2 POLYMERASE CHAIN REACTION 99
8.7.2.3 ELISA 99
8.7.2.4 DNA STAINING/INDIRECT ASSAY 99
8.7.2.5 ENZYMATIC METHODS 99
8.7.2.6 OTHERS 99
9 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY END USER 100
9.1 OVERVIEW 101
9.2 HOSPITALS 102
9.3 DIAGNOSTIC LABORATORIES 102
9.4 OTHERS 103
10 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, BY GEOGRAPHY 104
10.1 OVERVIEW 105
10.2 NORTH AMERICA 110
10.2.1 U.S. 119
10.2.2 CANADA 125
10.2.3 MEXICO 131
10.3 EUROPE 137
10.3.1 GERMANY 147
10.3.2 U.K. 153
10.3.3 FRANCE 159
10.3.4 ITALY 165
10.3.5 SPAIN 171
10.3.6 NETHERLANDS 177
10.3.7 SWITZERLAND 183
10.3.8 RUSSIA 189
10.3.9 BELGIUM 195
10.3.10 TURKEY 201
10.3.11 REST OF EUROPE 206
10.4 ASIA-PACIFIC 207
10.4.1 JAPAN 217
10.4.2 CHINA 223
10.4.3 INDIA 229
10.4.4 SOUTH KOREA 235
10.4.5 AUSTRALIA 241
10.4.6 SINGAPORE 247
10.4.7 MALAYSIA 253
10.4.8 INDONESIA 259
10.4.9 THAILAND 265
10.4.10 PHILIPPINES 271
10.4.11 REST OF ASIA-PACIFIC 277
10.5 SOUTH AMERICA 278
10.5.1 BRAZIL 287
10.5.2 REST OF SOUTH AMERICA 293
10.6 MIDDLE EAST & AFRICA 294
10.6.1 SOUTH AFRICA 303
10.6.2 REST OF MIDDLE EAST & AFRICA 309
11 GLOBAL MYCOPLASMA TESTING IN CLINICAL MARKET, COMPANY LANDSCAPE 310
11.1 COMPANY SHARE ANALYSIS: GLOBAL 310
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 311
11.3 COMPANY SHARE ANALYSIS: EUROPE 312
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 313
12 COMPANY PROFILE 314
12.1 BIO-RAD LABORATORIES, INC. 314
12.1.1 COMPANY SNAPSHOT 314
12.1.2 REVENUE ANALYSIS 314
12.1.3 COMPANY SHARE ANALYSIS 315
12.1.4 PRODUCT PORTFOLIO 315
12.1.5 RECENT DEVELOPMENTS 316
12.2 MERCK KGAA 317
12.2.1 COMPANY SNAPSHOT 317
12.2.2 REVENUE ANALYSIS 317
12.2.3 COMPANY SHARE ANALYSIS 318
12.2.4 PRODUCT PORTFOLIO 318
12.2.5 RECENT DEVELOPMENT 318
12.3 BIOMeRIEUX SA 319
12.3.1 COMPANY SNAPSHOT 319
12.3.2 REVENUE ANALYSIS 319
12.3.3 COMPANY SHARE ANALYSIS 320
12.3.4 PRODUCT PORTFOLIO 320
12.3.5 RECENT DEVELOPMENTS 321
12.4 SARTORIUS AG 322
12.4.1 COMPANY SNAPSHOT 322
12.4.2 REVENUE ANALYSIS 322
12.4.3 COMPANY SHARE ANALYSIS 323
12.4.4 PRODUCT PORTFOLIO 323
12.4.5 RECENT DEVELOPMENTS 324
12.5 AB ANALITICA SRL 325
12.5.1 COMPANY SNAPSHOT 325
12.5.2 PRODUCT PORTFOLIO 325
12.5.3 RECENT DEVELOPMENTS 326
12.6 AGILENT TECHNOLOGIES, INC. 327
12.6.1 COMPANY SNAPSHOT 327
12.6.2 REVENUE ANALYSIS 327
12.6.3 PRODUCT PORTFOLIO 328
12.6.4 RECENT DEVELOPMENTS 329
12.7 ELITECHGROUP 330
12.7.1 COMPANY SNAPSHOT 330
12.7.2 PRODUCT PORTFOLIO 330
12.7.3 RECENT DEVELOPMENTS 331
12.8 GOLD STANDARD DIAGNOSTICS 332
12.8.1 COMPANY SNAPSHOT 332
12.8.2 PRODUCT PORTFOLIO 332
12.8.3 RECENT DEVELOPMENTS 333
12.9 LIOFILCHEM SRL 334
12.9.1 COMPANY SNAPSHOT 334
12.9.2 PRODUCT PORTFOLIO 334
12.9.3 RECENT DEVELOPMENTS 335
?
12.10 LONZA 336
12.10.1 COMPANY SNAPSHOT 336
12.10.2 REVENUE ANALYSIS 336
12.10.3 PRODUCT PORTFOLIO 337
12.10.4 RECENT DEVELOPMENTS 337
12.11 OPERON 338
12.11.1 COMPANY SNAPSHOT 338
12.11.2 PRODUCT PORTFOLIO 338
12.11.3 RECENT DEVELOPMENTS 339
12.12 OSANG HEALTHCARE 340
12.12.1 COMPANY SNAPSHOT 340
12.12.2 PRODUCT PORTFOLIO 340
12.12.3 RECENT DEVELOPMENT 340
12.13 PROMOCELL GMBH 341
12.13.1 COMPANY SNAPSHOT 341
12.13.2 PRODUCT PORTFOLIO 341
12.13.3 RECENT DEVELOPMENTS 342
12.14 F. HOFFMANN-LA ROCHE LTD 343
12.14.1 COMPANY SNAPSHOT 343
12.14.2 REVENEUE ANALYSIS 343
12.14.3 PRODUCT PORTFOLIO 344
12.14.4 RECENT DEVELOPMENTS 344
12.15 SACACE BIOTECHNOLOGIES SRL 345
12.15.1 COMPANY SNAPSHOT 345
12.15.2 PRODUCT PORTFOLIO 345
12.15.3 RECENT DEVELOPMENT 346
12.16 SEEGENE INC. (2018) 347
12.16.1 COMPANY SNAPSHOT 347
12.16.2 REVENUE ANALYSIS 347
12.16.3 PRODUCT PORTFOLIO 348
12.16.4 RECENT DEVELOPMENTS 349
12.17 THERMO FISHER SCIENTIFIC INC. 351
12.17.1 COMPANY SNAPSHOT 351
12.17.2 REVENUE ANALYSIS 351
12.17.3 PRODUCT PORTFOLIO 352
12.17.4 RECENT DEVELOPMENT 352
12.18 ZEAKON DIAGNOSTICS 353
12.18.1 COMPANY SNAPSHOT 353
12.18.2 PRODUCT PORTFOLIO 353
12.18.3 RECENT DEVELOPMENT 354
13 SWOT AND DBMR ANALYSIS 355
14 CONCLUSION: 357
15 QUESTIONNAIRE 358
16 RELATED REPORTS 367